Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
7 hedge funds and large institutions have $284K invested in Lipella Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
9% more capital invested
Capital invested by funds: $260K → $284K (+$24K)
2.21% more ownership
Funds ownership: 6.08% → 8.28% (+2.2%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
22% less funds holding
Funds holding: 9 → 7 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$198K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.99K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$33 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$11K |
| 3 |
HF
HRT Financial
New York
|
-$7K |
| 4 |
Two Sigma Investments
New York
|
-$65 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$45 |
LIPO Hedge Fund Activity: Q2 2024 in Review
7 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q2 2024, worth a combined $284K — up 9.2% from $260K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LIPO and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Sabby Management, adding an estimated $198K. The largest seller was Citadel Advisors, exiting entirely with an estimated $15.1K sold.
- 7 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q2 2024, down from 9 in Q1 2024.
- Funds reported $284K of Lipella Pharmaceuticals stock for Q2 2024, up 9.2% quarter-over-quarter.
- 2 funds opened new Lipella Pharmaceuticals positions in Q2 2024 and 4 closed out, a net change of -2 holders.
- The largest Lipella Pharmaceuticals buyer in Q2 2024 was Sabby Management, an estimated $198K added.
- The largest Lipella Pharmaceuticals seller in Q2 2024 was Citadel Advisors, an estimated $15.1K sold.
Based on aggregated 13F filings for Q2 2024.